Definition
Isoprostane refers to a family of prostaglandin‑like compounds generated in vivo through free‑radical–mediated peroxidation of polyunsaturated fatty acids, most notably arachidonic acid. Unlike classical prostaglandins, which are synthesized enzymatically by cyclooxygenase (COX) isoforms, isoprostanes are formed non‑enzymatically and are widely regarded as reliable biomarkers of oxidative stress in biological systems.
Overview
Isoprostanes are produced when reactive oxygen species (ROS) abstract a hydrogen atom from the bis‑allylic position of arachidonic acid, initiating a chain reaction that yields a series of peroxyl radicals. Subsequent cyclization and rearrangement generate a series of regio‑ and stereoisomeric compounds possessing a cyclopentane ring and a 20‑carbon backbone, structurally analogous to prostaglandins. The most extensively studied member is 8‑iso‑prostaglandin F₂α (8‑iso‑PGF₂α), often measured in plasma, urine, and tissue extracts to assess oxidative injury in clinical and experimental contexts.
Key points regarding isoprostanes include:
- Formation pathway – Occurs independently of COX enzymes; driven by ROS such as hydroxyl radicals, superoxide, and peroxynitrite.
- Biological activity – Certain isoprostanes exhibit vasoconstrictive, platelet‑activating, and inflammatory properties, influencing vascular tone and thrombosis.
- Clinical relevance – Elevated isoprostane levels have been documented in a variety of conditions associated with oxidative stress, including cardiovascular disease, neurodegeneration, diabetes, smoking, and exposure to environmental pollutants.
- Analytical measurement – Quantification is typically performed using mass spectrometry (GC‑MS or LC‑MS/MS) or immunoassays, with urinary 8‑iso‑PGF₂α being a common non‑invasive index.
Etymology / Origin
The term combines the prefix “iso‑,” meaning “similar” or “like,” with “prostane,” derived from “prostaglandin.” This reflects the compounds’ structural resemblance to prostaglandins while emphasizing their distinct, non‑enzymatic origin.
Characteristics
| Property | Description |
|---|---|
| Chemical class | Eicosanoids; prostaglandin‑like lipid mediators |
| Precursors | Arachidonic acid (20:4 n‑6) and, to a lesser extent, other polyunsaturated fatty acids (e.g., eicosapentaenoic acid) |
| Molecular structure | Cyclopentane ring with two hydroxyl groups, a keto group (in F₂ series), and a 20‑carbon tail; exists as multiple regio‑ and stereoisomers (e.g., 8‑iso‑PGF₂α, 15‑iso‑PGF₂α) |
| Formation mechanism | Free‑radical–catalyzed peroxidation; does not require COX enzymes |
| Stability | Relatively stable compared with primary lipid peroxides, permitting detection in biological fluids |
| Physiological effects | Can bind to prostaglandin receptors (e.g., TP receptor) and modulate vasomotor tone, platelet aggregation, and inflammatory signaling |
| Analytical detection | Typically measured by gas or liquid chromatography coupled with mass spectrometry; immunoassays are also used for high‑throughput screening |
Related Topics
- Prostaglandins – Enzymatically derived eicosanoids produced via cyclooxygenase pathways.
- Lipid peroxidation – Oxidative degradation of lipids leading to the formation of reactive aldehydes and isoprostanes.
- Oxidative stress – Imbalance between ROS production and antioxidant defenses, a condition wherein isoprostanes serve as biomarkers.
- Arachidonic acid metabolism – Central to the generation of both enzymatic eicosanoids (prostanoids, leukotrienes) and non‑enzymatic products like isoprostanes.
- Cyclooxygenase (COX) enzymes – Enzymes responsible for classical prostaglandin synthesis; their inhibition does not affect isoprostane formation.
- Biomarkers of disease – Isoprostanes are employed in research and clinical studies to monitor oxidative damage in cardiovascular disease, neurodegeneration, renal pathology, and lifestyle factors (e.g., smoking).
Note: The information presented reflects current scientific consensus as of the latest peer‑reviewed literature.